Literature DB >> 22728005

Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Ramin S Hastings1, Judith S Hochman, Vladimir Dzavik, Gervasio A Lamas, Sandra A Forman, Francois Schiele, Lampros K Michalis, Dimitris Nikas, Joanna Jaroch, Harmony R Reynolds.   

Abstract

Renal dysfunction is an independent predictor of cardiovascular events and a negative prognostic indicator after myocardial infarction (MI). Randomized data comparing percutaneous coronary intervention to medical therapy in patients with MI with renal insufficiency are needed. The Occluded Artery Trial (OAT) compared optimal medical therapy alone to percutaneous coronary intervention with optimal medical therapy in 2,201 high-risk patients with occluded infarct arteries >24 hours after MI with serum creatinine levels ≤2.5 mg/dl. The primary end point was a composite of death, MI, and class IV heart failure (HF). Analyses were carried out using estimated glomerular filtration rate (eGFR) as a continuous variable and by eGFR categories. Long-term follow-up data (maximum 9 years) were used for this analysis. Lower eGFR was associated with development of the primary outcome (6-year life-table rates of 16.9% for eGFR >90 ml/min/1.73 m(2), 19.2% for eGFR 60 to 89 ml/min/1.73 m(2), and 34.9% for eGFR <60 ml/min/1.73 m(2); p <0.0001), death, and class IV HF, with no difference in rates of reinfarction. On multivariate analysis, eGFR was an independent predictor of death and HF. There was no effect of treatment assignment on the primary end point regardless of eGFR, and there was no significant interaction between eGFR and treatment assignment on any outcome. In conclusion, lower eGFR at enrollment was independently associated with death and HF in OAT participants. Despite this increased risk, the lack of benefit from percutaneous coronary intervention in the overall trial was also seen in patients with renal dysfunction and persistent occlusion of the infarct artery in the subacute phase after MI.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22728005      PMCID: PMC3439588          DOI: 10.1016/j.amjcard.2012.05.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Design and methodology of the Occluded Artery Trial (OAT).

Authors:  Judith S Hochman; Gervasio A Lamas; Genell L Knatterud; Christopher E Buller; Vladimir Dzavik; Daniel B Mark; Harmony R Reynolds; Harvey D White
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

3.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

Authors:  P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

4.  Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction.

Authors:  Vinod Jorapur; Gervasio A Lamas; Zygmunt P Sadowski; Harmony R Reynolds; Antonio C Carvalho; Christopher E Buller; James M Rankin; Jean Renkin; Philippe Gabriel Steg; Harvey D White; Carlos Vozzi; Eduardo Balcells; Michael Ragosta; C Edwin Martin; Vankeepuram S Srinivas; William W Wharton Iii; Staci Abramsky; Ana C Mon; Shari S Kronsberg; Judith S Hochman
Journal:  World J Cardiol       Date:  2010-01-26

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.

Authors:  Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas
Journal:  Circulation       Date:  2011-10-24       Impact factor: 29.690

7.  Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease.

Authors:  Donal N Reddan; Lynda Anne Szczech; Robert H Tuttle; Linda K Shaw; Robert H Jones; Steve J Schwab; Mark Stafford Smith; Robert M Califf; Daniel B Mark; William F Owen
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

8.  Association of CKD and cancer risk in older people.

Authors:  Germaine Wong; Andrew Hayen; Jeremy R Chapman; Angela C Webster; Jie Jin Wang; Paul Mitchell; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 10.121

9.  Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

Authors:  Lin Zhao; Lei Wang; Yuchen Zhang
Journal:  J Invasive Cardiol       Date:  2009-10       Impact factor: 2.022

10.  Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events).

Authors:  Caroline Medi; Gilles Montalescot; Andrzej Budaj; Keith A A Fox; José López-Sendón; Gordon FitzGerald; David B Brieger
Journal:  JACC Cardiovasc Interv       Date:  2009-01       Impact factor: 11.195

View more
  1 in total

1.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.